In NSCLC patients with EGFR mutations, a rebound tumor flare, characterized by a sudden marked increase in tumor growth, with the worsening of disease-related symptoms, and increased radiological activity on positron emission tomography/computed tomography (PET-CT) scan, which can occur with the interruption of TKI in about 20% of the patients, may play a role in this choice [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.